We are a research-based biotechnology company focused on the discovery, development and licensing of novel disease-modifying therapeutics for the treatment and prevention of rare neurodegenerative, “orphan”, diseases with high unmet medical need. Our internal drug discovery programs are focused on therapeutic applications of monoclonal antibodies.
We have a strong track record of executing successful license agreements with leading pharmaceutical companies. As an example, we licensed a naturally derived, small molecule, potent antioxidant to Shire Plc (“Shire”), which tested the drug candidate in patients with Freidreich’s Ataxia, a rare, hereditary disorder that leads to progressive and irreversible damage to the nervous system.. Friedreich’s Ataxia affects an estimated 1 in 30,000 to 50,000 people in the United States and a similar number in ex-US countries.
Our global patent estate, which includes 85 issued patents spanning composition of matter and methods of use of various compounds for the treatment of neurodegenerative diseases (e.g. tauopathies and proteinopathies), protects our proprietary interest in novel antioxidants, amyloid beta monoclonal antibodies, tau monoclonal antibodies and related platform technologies.